AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Dec 2019 03:00 PM
RNS
Block listing Interim Review
29 Nov 2019 07:00 AM
RNS
Imfinzi granted FDA Priority Review for SCLC
21 Nov 2019 06:15 PM
RNS
Calquence approved in CLL in the US
15 Nov 2019 07:00 AM
RNS
Qtrilmet approved in the EU for treatment of T2D
14 Nov 2019 07:00 AM
RNS
FDA accepts regulatory submission for selumetinib
12 Nov 2019 07:00 AM
RNS
Anifrolumab demonstrated superiority in TULIP 2
11 Nov 2019 07:00 AM
RNS
Roxadustat pooled analyses: no increased CV risk
08 Nov 2019 07:00 AM
RNS
Roxadustat significantly increased haemoglobin
06 Nov 2019 02:10 PM
RNS
Calquence data to show improved progression-free
01 Nov 2019 03:00 PM
RNS
Total Voting Rights
30 Oct 2019 07:00 AM
RNS
AstraZeneca divests rights to Seroquel and
28 Oct 2019 03:31 PM
RNS
Imfinzi and Imfinzi plus tremelimumab delayed
24 Oct 2019 07:00 AM
RNS
AstraZeneca year-to-date and Q3 2019 results
21 Oct 2019 07:00 AM
RNS
Farxiga approved in the US to reduce the risk of
17 Oct 2019 07:00 AM
RNS
Trastuzumab deruxtecan granted FDA Priority Review
04 Oct 2019 03:04 PM
RNS
Holding(s) in Company
04 Oct 2019 03:00 PM
RNS
Holding(s) in Company
04 Oct 2019 07:00 AM
RNS
Fasenra approved in the US for self-administration
03 Oct 2019 04:00 PM
RNS
Director Declaration
01 Oct 2019 03:00 PM
RNS
Total Voting Rights
01 Oct 2019 07:05 AM
RNS
AstraZeneca divests rights for Losec to Cheplaphar
01 Oct 2019 07:00 AM
RNS
Update on US regulatory review of PT010 in COPD
30 Sep 2019 03:30 PM
RNS
Lynparza more than doubled the time without
30 Sep 2019 07:00 AM
RNS
Tagrisso is the only 1st-line treatment for EGFR-
30 Sep 2019 07:00 AM
RNS
Lynparza improved the time women lived without
23 Sep 2019 07:00 AM
RNS
Qtrilmet recommended for approval in EU by CHMP
18 Sep 2019 07:00 AM
RNS
AstraZeneca amends collaboration with Ironwood
09 Sep 2019 08:38 AM
RNS
Imfinzi is first immunotherapy to show both
04 Sep 2019 07:11 AM
RNS
Tagrisso approved in China as a 1st-line treatment
02 Sep 2019 03:00 PM
RNS
Total Voting Rights
02 Sep 2019 07:05 AM
RNS
Brilinta reduced the risk of cardiovascular events
02 Sep 2019 07:00 AM
RNS
Detailed results from Phase III DAPA-HF trial
29 Aug 2019 07:00 AM
RNS
Anifrolumab Phase III trial meets primary endpoint
28 Aug 2019 07:05 AM
RNS
Fasenra granted US Orphan Drug Designation for
28 Aug 2019 07:00 AM
RNS
Breztri Aerosphere Phase III ETHOS trial met
22 Aug 2019 07:00 AM
RNS
Roxadustat approved in China for the treatment of
22 Aug 2019 07:00 AM
RNS
AstraZeneca agrees to buy US FDA Priority Review
21 Aug 2019 07:00 AM
RNS
Update on the Phase III NEPTUNE trial
20 Aug 2019 07:00 AM
RNS
Farxiga met primary endpoint in landmark Phase III
19 Aug 2019 07:00 AM
RNS
Directorate Change
14 Aug 2019 07:00 AM
RNS
Lynparza Phase III PAOLA-1 trial met primary endpo
14 Aug 2019 07:00 AM
RNS
Calquence granted US Breakthrough Therapy Designat
09 Aug 2019 09:28 AM
RNS
Amendment: Tagrisso significantly improves overall
09 Aug 2019 07:00 AM
RNS
Tagrisso significantly improves overall survival
07 Aug 2019 07:00 AM
RNS
Lynparza Phase III PROfound trial in HRR*
05 Aug 2019 07:00 AM
RNS
Forxiga label updated in the EU in type-2 diabetes
01 Aug 2019 03:00 PM
RNS
Total Voting Rights
25 Jul 2019 07:00 AM
RNS
AZN: H1 2019 Results
15 Jul 2019 07:00 AM
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 07:00 AM
RNS
Imfinzi granted US Orphan Drug Designation for

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings